Sinopharm 

HK$16.82
43
-HK$0.24-1.41% Thursday 08:08

Statistik

Harga Tertinggi Hari
17.3
Harga Terendah Hari
16.68
52M Tertinggi
23
52M Terendah
16.68
Volum
10,652,566
Volum Purata
5,532,884
Kapasiti Pasaran
63.51B
Nisbah P/E
7.22
Pendapatan Dividen
5.68%
Dividen
0.96

Akan Datang

Dividen

5.68%Pendapatan Dividen
Pertumbuhan 10T
11.31%
Pertumbuhan 5T
7.33%
Pertumbuhan 3T
4.43%
Pertumbuhan 1T
6.09%

Pendapatan

25AugDijangka
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
0.69
1.04
1.4
1.75
EPS yang dijangka
1.4800067469359999
EPS sebenar
1.2762377020679998

Orang Lain Juga Mengikuti

Senarai ini berdasarkan senarai pantau orang di Stock Events yang mengikuti 1099.HK. Ini bukan cadangan pelaburan.

Peserta

Senarai ini adalah analisis berdasarkan peristiwa pasaran terkini. Ini bukan cadangan pelaburan.

Mengenai

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.
Show more...
CEO
Mr. Qingming Yu
Pekerja
113234
Negara
Hong Kong
ISIN
CNE100000FN7

Penyenaraian